Handbook of analytical validation

Handbook of Analytical Validation

Volumn , Issue , 2012, Pages 1-197

  Swartz, Michael E ^a   Krull, Ira S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122904325     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (208)

1. http://www.fda.gov/cder/handbook/develop.htm.
2. FDA Guidance for Industry, IND's for Phase 2 and 3 Studies of Drugs, Chemistry, Manufacturing and Controls, Content and Format, Draft Guidance, CBER and CDER, February 1999. See http://www.fda.gov/cder/guidance/guidance.htm.
3. Boudreau, S. P., McElvain, J. S., Martin, L. D., Dowling, T., and Fields, S. M., Method validation by phase of development, an acceptable analytical practice, Pharm. Technol., p. 54, November 2004.
4. DiMasi, J. A., Hansen, R. W., and Grabowski, H. G., The price of innovation: New estimates of drug development costs, J. Health Economics, 22, 151, 2003.
5. Tufts Center for the Study of Drug Development, Press release Nov. 9, 2006, and May 13, 2009. See http://csdd.tufts.edu.
6. http://www.fda.gov/opacom/morechoices/mission.html.
7. ICH Q2A: Text on validation of analytical procedures, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, March 1995, Fed. Reg., Vol. 60, March 1, 1995, p. 11260. See also www.ich.org.
8. ICH Q2B: Validation of analytical procedures: Methodology, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, May 1997, Fed. Reg., Vol. 62, No. 96, May 19, 1997, pp. 27463-27467. See also www.ich.org.
9. ICH Q2 (R1): Validation of analytical procedures: Text and methodology, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, November 2005. See also www.ich.org.
10. United States Food and Drug Administration, Guideline for submitting samples and analytical data for methods validation, February 1987. US Government Printing Office: 1990-281-794:20818, or at www.fda.gov/cder/analyticalmeth.htm.
11. Draft Guidance for Industry: Analytical Procedures and Methods Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Division of Research, Rockville, MD, August 2000.
12. Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 211, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
13. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1225>.
14. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, 21 CFR Part 210, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
15. FDA, General Principles of Software Validation; Guidance for Industry and FDA Staff. See http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085371.pdf.
16. FDA Guidance for Industry, Computerized Systems Used in Clinical Investigations, May 2007. See http://www.fda.gov/cder/guidance/7359fnl.htm.
17. FDA, 21 CFR Part 11, Electronic Records; Electronic Signatures; Final Rule. Fed. Reg., Vol. 62, No. 54, p. 13429, March 20, 1997.
18. FDA, CFR Part 11, Electronic Records; Electronic Signatures-Scope and Application, 2003. See http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072322.pdf.
19. Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach, AAPS PharmSciTech, 2004, 5(1) Article 22 (http://www.aapspharmscitech.org).
20. Hertzog, D. L., et al., Developed and validated stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products, Pharm. Forum, 31(5), Sept-Oct 2005, pp. 1453-1463.
21. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1058>.
22. Swartz, M. E., Analytical Instrument Qualification, Pharmaceutical Regulatory Guidance Book, Advanstar (publisher), Supplement to LC6C Magazine Santa Monica CA, pp. 12-16, July 2006.
23. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <621>.
24. www.fda.gov/foi/warning.htm and search for "Training" for more examples.
25. Swartz, M.E. and Krull I.S., Analytical Method Development and Validation, Marcel Dekker, New York, 1997.
26. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, 21 CFR Part 210, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
27. Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 211, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
28. United States Food and Drug Administration, Guideline for Submitting Samples and Analytical Data for Methods Validation, February 1987. US Government Printing Office: 1990-281-794:20818, or at www.fda.gov/cder/analyticalmeth.htm.
29. Draft Guidance for Industry: Analytical Procedures and Methods Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Division of Research, Rockville, MD, August 2000.
30. ICH Q2 (R1): Validation of analytical procedures: Text and methodology, International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, November 2005. See also www.ich.org.
31. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1225>.
32. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <621>.
33. Hertzog, D.L. et al., Developed and validated stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorthiazide, and their degradation products, Pharm. Forum, 31(5), L10587, Analytics Instrument Qualification Sept-Oct 2005, pp. 1453-1463.
34. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1058>.
35. Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach, AAPS PharmSciTech, 2004, 5(1) Article 22 (http://www.aapspharmscitech.org).
36. Development and Validation of Analytical Methods, C. M. Riley and T.W. Rosanske, Editors, Pergamon Press, Elsevier Science, Amsterdam, Holland, 1996.
37. Pharmaceutical and Biomedical Applications of Liquid Chromatography, C. M. Riley, W. J. Lough, and I.W. Wainer, Editors, Pergamon Press, Elsevier Science, Amsterdam, Holland, 1994.
38. Snyder, L. R., Glajch, J. L., and Kirkland, J. J., Practical HPLC Method Development, John Wiley & Sons, New York, 1988.
39. Snyder, L. R., Glajch, J. L., and Kirkland, J. J., Practical HPLC Method Development, 2nd edition, Wiley-Interscience, New York, 1997.
40. Neue, U., HPLC Columns, Theory, Technology, and Practice, Wiley-VCH Publishers, New York, 1997.
41. Snyder, L. R., Kirkland, J. J., and Dolan, J. W., Introduction to Modern Liquid Chromatography, 3rd edition, John Wiley & Sons, Hoboken, NJ, 2010.
42. Swartz, M. E., Chapter 6: Contemporary liquid chromatographic systems for method development, pp. 145-186, in HPLC Method Development for Pharmaceuticals, Ahuja, S., Editor, Elsevier, Burlington, MA, 2007.
43. Dolan, J. W., Snyder, L. R., Djordjevic, N. M., Hill, D. W., Saunders, D. L. Van Heukelemn, L., and Waeghe, T. J. Simultaneous variation of temperature and gradient steepness for reversed-phase high-performance liquid chromatography method development. I. Application to 14 different samples using computer simulation. J. Chromatogr., A, 803, 1, 1998.
44. Dolan, J. W., Snyder, L. R., Saunders, D. L., and Van Heukelem, L., Simultaneous variation of temperature and gradient steepness for reversed-phase high-performance liquid chromatography method development. II. The use of further changes in conditions. J. Chromatogr., A, 803, 33, 1998.
45. Dolan, J. W., Snyder, L. R., Djordjevic, N. M., Hill, D. W., and Waeghe, T. J., Reversedphase liquid chromatographic separation of complex samples by optimizing temperature and gradient time. I. Peak capacity limitations. J. Chromatogr., 857, 1, 1999.
46. Dolan, J. W., Snyder, L. R., Wolcott, R. G., Haber, P., Baczek, T., Kaliszan, R., and Sander L.C., Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time. III. Improving the accuracy of computer simulation. J. Chromatogr., A, 857, 41, 1999.
47. Dolan, J. W., Snyder, L. R., Djordjevic, N. M., Hill, D. W., and Waeghe, T. J. Reversedphase liquid chromatographic separation of complex samples by optimizing temperature and gradient time. II. Two-run assay procedures. J. Chromatogr., A, 857, 21, 1999.
48. Molnar. I. Computerized design of separation strategies by reversed-phase liquid chromatography: Development of DryLab software. J. Chromatogr., A, 965, 175, 2002.
49. Swartz, M. E., Jones, M., Fowler, P., and Andrews, M., Automated HPLC Method Development and Transfer. LCGC, 20(6), 43, June 2002.
50. Jerkovitch, A. D., Mellors, J. S., and Jorgenson, J. W. The Use of Micron-Sized Particles n Ultrahigh-Pressure Liquid Chromatography. LCGC North America, 21(7), 2003.
51. The Quest for Ultra Performance in Liquid Chromatography-Origins of UPLC Technology, Waters Corporation. See http://www.waters.com/waters/partDetail.htm?cid=511539&id=38628&ev=10120661&locale=en_US.
52. Beginners Guide to UPLC-Ultra-Performance Liquid Chromatography. Waters Corporation. See http://www.waters.com/waters/partDetail.htm?cid=511539&id=38629&ev=10120684&locale=en_US.
53. Swartz, M.E. and Murphy, B., UPLC: An introduction and review. J. Liq. Chrom.Related Tech., 28, 1253, 2005.
54. Swartz, M. E. and Plumb, R., Waters Corporation, Milford, MA, unpublished data.
55. Lukaly, P., Pfizer, Ann Arbor MI, personal communication.
56. Swartz, M. E., HPLC Systems and Components Introduced at Pittcon 2010: A Brief Review. LCGC, 28(5), 376, May 2010.
57. Corona Charged Aerosol Detector, brochure 70-6454 Rev A, ESA/Dionex, Chelmsford, MA, 2004.
58. Swartz, M., Emanuele, M., Awad, A., and Hartley, D., Supplement to LC/GC North America, April 2009. See http://chromatographyonline.findanalytichem.com/lcgc/article/ articleDetail.jsp?id=592237&sk=&date=&pageID=2.
59. Niessen, W. M. A., Liquid Chromatography-Mass Spectrometry, Chromatographic Science Series Vol. 97, 3rd ed., Taylor & Francis, London, 2006.
60. McMaster, M. C., LC-MS: A Practical Users Guide, Wiley, Hoboken, NJ, 2005.
61. See http://www.usp.org/USPNF/columnsDB.html.
62. Guideline for Submitting Samples and Analytical Data for Methods Validation, USFDACDER (February 1987), http://www.fda.gov/cder/guidance/ameth.htm.
63. Chapter 1225, Validation of Compendial Methods, United States Pharmacopeia No.34-NF 297, (2011).
64. Analytical Procedures and Methods Validation, USFDA-CDER (August 2000), http://www.fda.gov/cder/guidance/2396dft.htm.
65. Harmonized tripartite guideline, validation of analytical procedures, text and methodology, Q2 (R1) International Conference on Harmonization, November 2005, http://www.ich.org/LOB/media/MEDIA417.pdf.
66. Guidance for Methods Development and Methods Validation for the Resource Conservation and Recovery Act (RCRA) Program, U.S. EPA (1995), http://www.epa.gov/epawaste/hazard/testmethods/pdfs/methdev.pdf.
67. ISO/IEC 17025, General requirements for the competence of testing and calibration laboratories, 2005, http://www.iso.org/iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=39883.
68. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, 21 CFR Part 210, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
69. Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 211, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
70. International Organization for Standardization, http://www.iso.org/iso/home.htm.
71. Reviewer Guidance, Validation of Chromatographic Methods, USFDA (November 1994) http://www.fda.gov/cder/guidance/cmc3.pdf.
72. Snyder, L. R., Kirkland, J. J., and Glajch, J. L. Practical HPLC Method Development, 2nd ed., Wiley-Interscience, New York, 1997.
73. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1225>.
74. International Conference on Harmonization, Harmonized tripartite guideline, validation of analytical procedures, text and methodology, Q2 (R1), November 2005. See www.ICH.org.
75. ISO/IEC 17025, General Requirements for the Competence of Testing and Calibration Laboratories, (2005), http://www.iso.org/iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=39883.
76. Box, G. E. P., Hunter, W. G., and Hunter, J. S., Statistics for Experimenters, John Wiley & Sons, New York, 1978.
77. Miller, J. C. and Miller, J. N., Statistics for Analytical Chemistry, Ellis Horwood Publishers, Chichester, UK, 1986.
78. NIST/SEMATECH e-Handbook of Statistical Methods, http://www.itl.nist.gov/div898/handbook.
79. Meier, P. C. and Zund, R. E., Statistical Methods in Analytical Chemistry, John Wiley & Sons, New York, 1993.
80. Plackett, R. L. and Burman, J. P., The Design of Optimum Multifactorial Experiments. Biometrika, 33, 305, 1946.
81. Ragonese, R., Mulholland, M., and Kalman, J., J. Chromatogr. A, 870, 45, 2000.
82. Nguyet, A. N. M., Tallieu, L., Plaizier-Vercammen, J., Massart, D. L., and Heyden, Y. V., Validation of an HPLC method on short columns to assay ketoconazole and formaldehyde in shampoo. Correct reference to read volume 32. J. Pharm. Biomed. Analysis, 21, 1-19, 2003.
83. Sun, S-W. and Su, H-T., Validated HPLC method for determination of sennosides A and B in senna tablets. J. Pharm. Biomed. Analysis, 29, 881-894, 2002.
84. Heyden, Y. V., Nijhuis, A., Smeyers-Verbek, B. G. M., and Massart, D. L., Guidance for robustness/ruggedness tests in method validation. J. Pharm. Biomed. Analysis, 24, 723-753, 2001.
85. Heyden, Y. V., Questier, F., and Massart, D. L., Ruggedness testing of chromatographic methods: selection of factors and levels. J. Pharm. Biomed. Analysis, 18, 43-56, 1998.
86. Questier, F., Heyden, Y. V., and Massart, D. L., RTS, a computer program for the experimental set-up and interpretation of ruggedness tests. J. Pharm. Biomed. Analysis, 18, 287-303, 1998.
87. Lukalay, P. and Morgado, J., Automation of the chromatographic analytical method validation process. LCGC, 24(2), 150-156, February 2006.
88. Empower 2 Software: Method Validation Manager, April 2007, 720001488EN LB-PC, Waters Corporation, Milford, MA.
89. The United States Pharmacopeia 34/ National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <621>.
90. Center for Drug Evaluation and Research (CDER), Reviewer Guidance: Validation of Chromatographic Methods, US Government Printing Office, 1994, 615-023-1302/02757.
91. Furman, W. B., Dorsey, J. G., and Snyder, L. R., System Suitability Tests in Regulatory Liquid and Gas Chromatographic Methods: Adjustments Versus Modifications. Pharm. Technol. 22(6), 58-64, 1998.
92. FDA ORA Laboratory Procedure, #ORA-LAB.5.4.5, Revised 09/09/2005. See also http://www.fda.gov/ora/science:ref/lm/vol2/section/5_04_05.pdf.
93. Pharm. Forum, 31(3), <621> Chromatography 825, May-June 2005.
94. Pharm. Forum, 31(6), <621> Chromatography 1681, Nov.-Dec. 2005.
95. Neue, N. D., McCabe, D., Ramesh, V., Pappa, H., and DeMuth, J., Stimuli to the revision process: Transfer of HPLC procedures to suitable columns of reduced dimensions and particle sizes. Pharm. Forum 35(6). April 2010.
96. Swartz, M. E., Unpublished data on the analysis of tricyclic amines at pH 7.2.
97. Swartz, M. E. and Krull, I. S., Developing and Validating Stability Indicating Methods. LCGC 23(6), 46, June 2005.
98. Swartz, M. E., UPLC: An introduction and review. J. Liq. Chromatogr. Rel. Technol., 28(7-8), 1253-1263, 2005.
99. Separation Science Re-Defined, Supplement to LCGC, May 2005.
100. Mazzeo, J., Neue, U., Kele, M., and Plumb, R., Advancing LC Performance with Smaller Particles and Higher Pressure. Anal. Chem., 77(23), 460A-467A, 2005.
101. The Quest for Ultra Performance in Liquid Chromatography-Origins of UPLC Technology, Waters Corporation. See http://www.waters.com/waters/partDetail.htm?cid=511539&id=38628&ev=10120661&locale=en_US.
102. Beginners Guide to UPLC-Ultra-Performance Liquid Chromatography. Waters Corporation. See http://www.waters.com/waters/partDetail.htm?cid=511539&id=38629&ev=10120684&locale=en_US.
103. ICH Q6A: Specifications for new drug substances and products: Chemical substances. International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, March 1995. See also www.ICH.org under topic of Quality guidelines.
104. ICH Q6A: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances, Fed. Reg., 65(251), 83041-83063, December 29, 2000, Notices. See also www.fda.gov/cder/guidance/index.htm under the topic of ICH Quality Guidelines.
105. Harmonized tripartite guideline, validation of analytical procedures, text and methodology, Q2 (R1). International Conference on Harmonization, November 2005, http://www.ich.org/LOB/media/MEDIA417.pdf.
106. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeia Convention, Inc., Rockville, MD, 2011, Chapter <1225>.
107. ICH Q2A(R): Impurities in new drug substances, Fed. Reg., 68(68), 6924-6925, Tuesday, February 11, 2003.
108. ICH Q3B(R): Impurities in new drug products, Fed. Reg., 68(220), 64628-64629, Friday, November 14, 2003.
109. ICH Q3C: Impurities: Residual solvents, Fed. Reg., 68(219), 64352-64353, Thursday, November 13, 2003.
110. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeia Convention, Inc., Rockville, MD, 2011, Chapter <467>.
111. Orr, J. D., Krull, I. S., and Swartz, M. E., Validation of impurity methods. Part 1, LC/GC Mag., 21(7), 626, 2003.
112. Orr, J. D., Krull, I. S., and Swartz, M. E., Validation of impurity methods. Part 2, LC/GC Mag., 21(12), 1146, 2003.
113. FDA's policy statement for the development of new stereoisomeric drugs. Chirality, 4, 338-340, 1992.
114. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeia Convention, Inc., Rockville, MD, 2011, Chapter <905>.
115. ICH Q1A (R2), Stability testing of new drugs and products, Fed. Reg., 68(225), Friday, November 21, 2003, pp. 65717-65718.
116. Guidance for Industry, Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production, U.S. Department of Health and Human Services FDA, September 1998.
117. Guidance for Industry, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research (CDER), October 2006. See also http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070287.pdf.21 CFR 10.115, Fed. Reg., 65(182), 56, 468-56, 480, September 19, 2000.
118. Analytical procedures and methods validation, Fed. Reg. 65(169), 52, 776-52, 777, August 30, 2000.
119. Brown R., Caphart, M., Faustino, P., Frankewich, R., Gibbs, J., Leutzinger, E., Lunn, G., Ng, L., Rajagopalan, R., Chui, Y., and Sheinin, E., LCGC, 19(1), 74-79, January 2001.
120. See http://srpub.phrma.org/letters/12.14.98.oos.commentary.html.
121. Kuwahara, S. S., Validation of impurity methods. Part1, LC/GC Mag., Biopharm Int., 11, 31-37, 2007.
122. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, 21 CFR Part 210, http://www.fda.gov/cder/dmpq/cg of Drugs/cgmpregs.htm.
123. Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 210, http://www.fda.gov/cder/dmpq/cgmpregs.htm.
124. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1225> Validation of compendial procedures.
125. Harmonized tripartite guideline, validation of analytical procedures, text and methodology, Q2 (R1), International Conference on Harmonization, November 2005, http://www.ich.org/LOB/media/MEDIA417.pdf.
126. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <467> Organic volatile impurities.
127. Draft Guidance for Industry: Analytical Procedures and Methods Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Division of Research, Rockville, MD, August 2000.
128. Reviewer Guidance: Validation of Chromatographic Methods, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD, November 1994.
129. ICH Q3A(R): Impurities in new drug substances, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, February 2002.
130. Repic, E., in Principles of Process Research and Development in the Pharmaceutical Industry, John Wiley & Sons, New York, 1998, pp. 1-54.
131. The United States Pharmacopeia 24/National Formulary 19, The United States Pharmacopeial Convention, Inc., Rockville, MD, 1999, Physical Tests, <281> Residue on ignition, p. 1862.
132. ICH Q7A: Good manufacturing practice guide for active pharmaceutical ingredients, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, November 2000.
133. The United States Pharmacopeia 34/National Formulary 29, The United States Pharacopeial Convention, Inc., Rockville, MD, 2011, General notices, significant figures and tolerances.
134. ICH Q1A(R2): Stability testing of new drug substances and products, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, February 2003.
135. ICH Q1B: Stability testing: Photostability testing of new drug substances and products, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, November 1996.
136. Reynolds, D. W., Forced degradation of Pharmaceuticals, Am. Pharm. Review, May/June, 56-61, 2004.
137. Swartz, M. E., Jones, M. D., and Andrews, M. A., Automated HPLC method development and transfer. LCGC Application Notebook, 66-67, June 2002.
138. Swartz, M. E., Chapter 6: Contemporary liquid chromatographic systems for method development, in HPLC Method Development for Pharmaceuticals, Volume 8, Ahuja, S., Editor, Elsevier, Boston, MA 2007.
139. Neue, U. D., Walter, T. H., Alden, B. A., Jiang, Z., Fisk, R. P., Cook, J. T., Glose, K. H., Carmody, J. L., Grassi, J. M., Cheng, Y.-F., Lu, Z., and Crowley, R. J., Ethylene bridged hybrids and their use in liquid chromatography, Part 1. Am. Lab., 31, 36, 1999.
140. Cheng, Y.-F., Walter, T. H., Lu, Z., Iraneta, P., Gendreau, C., Neue, U. D., Grassi, J. M., Carmody, J. L., O'Gara J.E., and Fisk, R. P., Ethylene bridged hybrids and their use in liquid chromatography, Part 2. 18, 1162, 2000.
141. Gorenstein, M. V., Li, J. B., Van Antwerp, J., and Chapman D., Detecting coeluted impurities by spectral comparison. LCGC 12(10), 768-772, 1994.
142. Young, P. M. and Gorenstein, M. V., Tryptic mapping by reversed-phase HPLC with photodiode-array detection incorporating the spectral-contrast technique. Elsevier, NY, 12(11), 832-838, 1994.
143. Warren, Wm. J., Stanick, W. A., Gorenstein, M. V., and Young, P. M., HPLC analysis of synthetic oligonucleotides using spectral contrast techniques. BioTechniques, Informa, London, 18(2), 282-297, 1995.
144. Swartz, M. E., UPLC: An introduction and review. J. Liq. Chrom., 28(7& 8), 1253-1263, 2005.
145. Swartz, M. E. and Murphy, B., New frontiers in chromatography; Introducing UPLC.Am. Lab. 37(3), 22-27, 2005.
146. The Quest for Ultra Performance in Liquid Chromatography-Origins of UPLC Technology, Waters Corporation. See http:// www.waters.com/ waters/ partDetail. html cid=511539&id=38628 &ev= 10120661&locale=en_US. Last accessed February 2012.
147. Beginners Guide to UPLC-Ultra-Performance Liquid Chromatography. Waters Corporation. See http://www.waters.com/ waters/partDetail.htm? cid=511539&id=38629&ev=10120684&locale=en_US.
148. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <701>, Disintegration.
149. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <711>, Dissolution.
150. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <724>, Drug Release.
151. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <1092>.
152. Guidance for Industry: The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2-Current Good Manufacturing Practice (CGMP), FDA Draft Guidance, October 2007. See www.fda.gov/cder/guidance/7232dft.htm.
153. FDA Division of Pharmaceutical Analysis, Mechanical Qualification of Dissolution apparatus 1 and 2, Document # DPA-LOP.002, Version 2.0, June 2006. See http://www.fda.gov/cder/offices/otr/dissolution.pdf.
154. AAPS PharmSciTech 2003; 4(1) article 7 (see www.pharmscitech.org).
155. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011, Chapter <621>, Chromatography.
156. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., and Yacobi, A., Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference Report. Pharm. Res., 9, 588, 1992.
157. Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tionelli, A., Viswanathan, C. T., and Yacobi, A., Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res., 17, 1551, 2000.
158. Viswanathan, C. T., Bansal, S., Booth, B., DeStafano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R., Workshop/Conference Report-Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. AAPS J., 9(1), 2007, E30. See also www.aapsj.org.
159. Guidance for Industry, Bioanalytical Method Validation, USFDA-CDER (May 2001), http://www.fda.gov/cder/guidance/4252fnl.pdf.
160. Viswanathan, C. T., Bansal, S., Booth, B., DeStafano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R., AAPS J., 9(1), 2007, E30. See also www.aapsj.org.
161. Hancock B, Editor. New Methods in Peptide Mapping for the Characterization of Proteins. CRC Press, Boca Raton, FL, 1996.
162. The United States Pharmacopeia 34/National Formulary 29 (The United States Pharmacopeial Convention, Inc., Rockville, MD, 2011), Chapter <1047>.
163. Mark-Varga, G. and Oroszlan, P., Editors, in Emerging Technologies in Protein and Genomic Material Analysis, Journal of Chromatography Library, 68, 188, 2003, Elsevier, Amsterdam.
164. Bongers, J., Cummings, J. J., Ebert, M. B., Federici, M. M., Gledhill, L., Gulati, D., Hilliard, G. M., Jones, B. H., Lee, K. R., Mozdzanowski, J., Naimoli, M., and Burman, S., Validation of a peptide mapping method for a therapeutic monoclonal antibody: what could we possibly learn about a method we have run 100 times? J. Pharm. Biomed. Anal., 21, 1099, 2000.
165. Code of Federal Regulations (CFR) 133.4, 1963.
166. Code of Federal Regulations (CFR) 211.67, 1978.
167. Valvis, I. I. and Champion, W. L. Jr., Cleaning and decontamination of potent compounds in the pharmaceutical Industry. Org. Process Res. Dev., 3, 44-52, 1999.
168. Harder, S. W., The validation of cleaning procedures. Pharm. Technol. 8(5), 29-34, 1987.
169. Smith, J. A., A modified swabbing technique for validation of detergent residues in clean-in-place systems. Pharm. Technol. 16(1), 60-66, 1992.
170. Fourman, G. L. and Mullen, M. V., Determining cleaning validation acceptance limits for pharmaceutical manufacturing. Pharm. Technol. 17(4), 54-60, 1993.
171. Zeller, A. O., Cleaning validation and residue limits: A contribution to current discussions. Pharm. Technol. 17(10), 70-80, 1993.
172. I.Losoxantrone., Shea J.A., Shamrock, W. F., Abboud C.A., Woodeshick R.W., Nguyen L.Q., Rubino J.T., and Segretario, J., Validation of cleaning procedures for highly potent drugs. Pharm. Dev. Technol. 1(1), 69-75, 1996.
173. Cleaning Validation Reprints from the Journal of Validation Technology, published by the Institute of Validation Technology, Royal Palm Beach, FL, 1998.
174. Guide to Inspections; Validation of Cleaning Processes, at www.fda.gov/ICECI/inspections/ inspectionguides/ucm074922.htm.
175. Guidance for Industry; Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients, p. 9-10, at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070289.pdf.
176. ISPE Good Practice Guide: Technology Transfer, March 2003. www.ispe.org/ispegood-practice-guides/technology-transfer.
177. PhRMA Analytical Research and Development Workshop, Wilmington, DC, September 20, 2000.
178. Scypinski, S., Roberts, D., Oates, M., and Etse, J., Pharm. Technol., March 2002, p. 84.
179. Mcgonigle, E., Assay validation and interlaboratory transfer in Development and Validation of Analytical Methods, Riley, C. M. and Rosanske, T. W., Editors, Elsevier, New York, 1996, p. 3.
180. Scypinski, S., Analytical method transfer, in Handbook of Modern Pharmaceutical Analysis, Ahuja, S. and Scypinski, S., Editors, Academic Press, San Diego, CA, 2001, p. 485.
181. Lister, A.S., in Handbook of Pharmaceutical Analysis by HPLC, Ahuja, S. and Dong, M., Editors, Elsevier, New York, 2005, p. 212.
182. Snyder, L. R., Kirkland, J. J., and Glajch, J. L., Chapter 15: Completing the method: Validation and transfer, in Practical HPLC Method Development, John Wiley & Sons, New York, 1997, p. 685.
183. Etse, J., Am. Pharm. Rev., January/February, 8(1), 74, 2005.
184. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeia Convention, Inc., Rockville, MD, 2011, Chapter <1225>.
185. International Conference on Harmonization. Harmonized tripartite guideline, validation of analytical procedures, text and methodology, Q2(R1), November 2005. See www.ICH.org.
186. Swartz, M. and Krull, I., Method Validation and Robustness. LCGC 24(5), 480, May 2006.
187. Swartz, M., Analytical Instrument Qualification. Pharmaceutical Technology Special Supplement, July 2006, p. 12.
188. Miller, J. C. and Miller, J. N., Statistics for Analytical Chemistry, Ellis Horwood Publishers, Chichester, UK, 1986.
189. NIST/SEMATECH e-Handbook of Statistical Methods, http://www.itl.nist.gov/div898/handbook.
190. Meier, P. C. and Zund, R. E., Statistical Methods in Analytical Chemistry, John Wiley & Sons, New York, 1993.
191. Snyder, L. R., Kirkland, J. J., and Glajch, J. L., Practical HPLC Method Development, John Wiley & Sons, New York, 1997.
192. M. Swartz, unpublished data.
193. Pappa, H. and Marques, M., Presentation at USP Annual Scientific Meeting, Denver, September 28, 2006. See also http://www.usp.org/USPNF/columns.html.
194. Swartz, M. E. and Krull, I. S., LCGC 23(10), 1100-1109, October 2005.
195. In-process revision, Pharm. Forum, 31(2), 555, Mar.-Apr. 2005.
196. FDA ORA Laboratory Procedure, #ORA-LAB.5.4.5, Revised 09/09/2005. See also http://www.fda.gov/ora/science:ref/lm/vol2/section/5_04_05.pdf.
197. Guidance for Industry, Changes to an Approved NDA or ANDA, FDA Center for Drug Evaluation and Research, Rockville MD, April 2004. See also http://www.fda.gov/cder/guidance/index.htm.
198. Guidance for Industry, Comparability Protocols-Chemistry, Manufacturing, and Controls Information, FDA Center for Drug Evaluation and Research, Rockville MD, February 2003. See also http://www.fda.gov/cder/guidance/index.htm.
199. Furman, W. B., Dorsey, J. G., and Snyder, L. R., Pharm. Technol. 22(6), 58-64, 1998.
200. Pharm. Forum, 31(3), 825, May-June 2005.
201. Pharm. Forum, 31(6), 1681, Nov.-Dec. 2005.
202. The United States Pharmacopeia 34/National Formulary 29, The United States Pharmacopeia Convention, Inc., Rockville, MD, 2011, Chapter <1226>.
203. Swartz, M. E., Krull, I. S., and McCabe, J., LCGC, 22(9), 906, 2004.
204. Current Good Manufacturing Practice for the Manufacture, Processing, Packing, or Holding of a Drug Product, 21 Code of Federal Register (CFR) Part 211; Subpart A: General Provisions 211.1-Scope.
205. Current Good Manufacturing Practice for the Manufacture, Processing, Packing, or Holding of a drug Product, 21 Code of Federal Register (CFR) Part 211; Subpart B: Organization and Personnel 211.25-Personnel Qualifications.
206. Neue, N. D., McCabe, D., Ramesh, V, Pappa, H., and DeMuth, J., Pharm. Forum, in press, April 2010.
207. Swartz, M. E. and Krull, I. S., LCGC, 23(6), 26, June 2004.
208. Guidance for Industry, Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production. U.S. Food and Drug Administration, Department of Health and Human Services, Rockville, MD, September 1998.